Log In
Print this Print this

PrEP-001 (formerly JNJ-43260295)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionNasally administered, broad-spectrum prophylactic agent
Molecular Target Undisclosed
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationViral respiratory infection
Indication DetailsTreat upper respiratory tract viral infections
Regulatory Designation
PartnerhVIVO plc;
PrEP Biopharm Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today